AnaptysBio (ANAB) stock news centers on a decisive legal victory that has fundamentally shifted the company's near-term risk profile. On Monday, AnaptysBio (ANAB) stock rose sharply, climbing over 17% to trade near $68.92, as the market digested a favorable ruling from the Delaware Court of Chancery. The court dismissed Tesaro’s anticipatory breach of contract claims, effectively removing the most significant legal overhang on AnaptysBio’s Jemperli royalty stream. While the broader market remained relatively flat, this idiosyncratic catalyst triggered a violent move in a stock that has been consolidating for months.
That said, the technical setup tells a more complex story than the headline news suggests. AnaptysBio has decisively broken above its 60-day high of $60.60, signaling a potential shift from a multi-month consolidation range into a new uptrend. The momentum is undeniable, with the Relative Strength Index (RSI) pushing into overbought territory at 80.31. However, the move is accompanied by a notable volume deficit. With relative volume sitting at just 0.58—meaning trading volume is roughly 42% below the 20-day average—the breakout lacks the broad institutional participation typically required to sustain a trend reversal. This divergence between price action and volume is the primary tension investors need to navigate right now.
Why is ANAB stock moving today?
The immediate driver of the move is a specific litigation event rather than broad market sentiment or sector rotation. The Delaware Court of Chancery’s dismissal of Tesaro’s claims eliminates a key legal challenge to AnaptysBio’s future revenue stream. For investors who had been wary of the pending litigation, this ruling serves as a clear green light, allowing the stock to re-rate higher. The timing is precise: the news broke late Sunday and early Monday, aligning perfectly with the pre-market surge that carried the stock above its recent resistance levels.
Even so, it is crucial to contextualize this move within the broader technical landscape. AnaptysBio has been trading in a defined range, with the $60.60 level acting as a structural ceiling for the past 60 days. By clearing this level, the stock has technically entered a breakout phase. The moving averages are now aligned bullishly, with the price trading well above both the 20-day and 50-day MAs. This structural break is significant because it removes the immediate supply zone that had capped the stock’s upside for months.
However, the lack of volume confirmation introduces a layer of fragility. In technical analysis, a breakout without volume is often viewed with skepticism. It suggests that the buying pressure may be driven by a few large players or short-covering rather than a wave of new institutional accumulation. If the buying interest does not expand in the next 1-2 sessions, the stock may struggle to hold these elevated levels. The RSI reading of 80.31 further supports the notion that the immediate upward pressure is exhausted, increasing the statistical probability of a pullback or sideways consolidation to digest the gains.
What traders should watch next
The most credible trade idea emerging from this setup is a "breakout retest" scenario. Rather than chasing the stock at these extended levels, the higher-probability play involves waiting for a pullback to the breakout zone between $60.60 and $65.00. If AnaptysBio can hold above this support area on decreasing volume, it would confirm that the breakout is genuine and that sellers are not flooding the market. Conversely, if the stock fails to hold $60.60, the breakout is invalidated, and the stock likely reverts to its previous consolidation range.
Crucially, traders should monitor the $70.00 level as the next major psychological and structural resistance. The stock touched $70.22 intraday but was rejected, leaving a wick that suggests selling pressure at this round number. A sustained close above $70.00 on above-average volume would be the strongest confirmation signal, indicating that the breakout has gained traction and is likely to continue toward higher targets like $71.00 or $75.00.
On the flip side, the bear case remains valid if the volume deficit persists. If AnaptysBio closes below $69.00 in the coming sessions without a clear catalyst to support the higher prices, the move could be dismissed as a "fake-out." A drop below $60.60 would be the primary invalidation level for the bullish thesis, signaling that the legal news was already priced in and that the underlying demand is insufficient to maintain the new higher valuation. Investors should also watch for any follow-up news or analyst commentary that might explain the low volume; if a major partnership or FDA update is announced, it could validate the move, but in the absence of such news, the technical risk of a mean reversion toward the 20-day moving average ($45.07) increases over time.
At the end of the day, the setup is conditional. The legal victory is a powerful fundamental catalyst, but the technical execution is incomplete without volume confirmation. Traders should approach this with caution, avoiding aggressive long positions until the $70.00 resistance is convincingly broken or a healthy pullback provides a clearer entry point. Understanding these ANAB support and resistance levels is essential for managing risk in a stock that is currently exhibiting extreme volatility and momentum.